Amgen and University of Washington’s Institute for Protein Design team up to build better cancer drugsGeekWire • 06/19/19
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents DataZacks Investment Research • 06/19/19
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise DealThe Motley Fool • 06/18/19
Amgen's early-stage study of cancer treatment had 'adverse events' in nearly half of its patientsMarket Watch • 06/05/19
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?Investors Business Daily • 06/03/19